ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Randomized Trial of Bupivacaine Versus Liposomal Bupivacaine in Minimally Invasive Lobectomy

Thursday, October 13, 2022

Submitted by

Cameron Lind

Source

Source Name: The Annals of Cardiothoracic Surgery

Source URL: https://doi.org/10.1016/j.athoracsur.2022.02.058

Author(s)

Sowmyanarayanan Thuppal, MD, PhD; Anthony Sleiman, BA; Kanika Chawla, MD; Danuta Dynda, MD; Quadis Evans, BS; Stephen Markwell, MA; Stephen Hazelrigg, MD; Traves Crabtree, MD

With the aim to compare the pain medicines bupivacaine and liposomal bupivacaine, minimally invasive lobectomy patients were randomly assigned to either medicine and monitored after surgery. Both postoperative pain level and treatment cost were compared. The study concluded that the morphine use, long-term narcotic use, and overall cost metrics between bupivacaine and LipoB were similar.